Arcturus Therapeutics
ARCT
179 hedge funds and large institutions have $919M invested in Arcturus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 55 increasing their positions, 62 reducing their positions, and 18 closing their positions.
83% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 18
15% more capital invested
Capital invested by funds: $802M → $919M (+$117M)
8% more funds holding
Funds holding: 165 → 179 (+14)
5.97% more ownership
Funds ownership: 95.16% → 101.13% (+6%)
1% less call options, than puts
Call options by funds: $11M | Put options by funds: $11.1M
11% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.9M |
| 2 |
BlackRock
New York
|
+$12.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.3M |
| 5 |
Morgan Stanley
New York
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$12.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.59M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$5.51M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$4.05M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$3.03M |
ARCT Hedge Fund Activity: Q1 2024 in Review
179 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2024, worth a combined $919M — up 15% from $802M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ARCT positions and 18 closed out — a net gain of 15 holders — while 55 added to existing stakes and 62 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $15.9M. The largest seller was ARK Investment Management, cutting an estimated $12.7M.
- 179 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2024, up from 165 in Q4 2023.
- Funds reported $919M of Arcturus Therapeutics stock for Q1 2024, up 15% quarter-over-quarter.
- 33 funds opened new Arcturus Therapeutics positions in Q1 2024 and 18 closed out, a net change of +15 holders.
- The largest Arcturus Therapeutics buyer in Q1 2024 was Adage Capital Partners, an estimated $15.9M added.
- The largest Arcturus Therapeutics seller in Q1 2024 was ARK Investment Management, an estimated $12.7M sold.
Based on aggregated 13F filings for Q1 2024.